BrainQ

BrainQ is a clinical-stage health technology company developing a non-invasive neurostimulation platform designed to promote recovery following neurological disorders such as stroke. The company's technology utilizes artificial intelligence to analyze brainwaves and deliver patient-specific, low-frequency electromagnetic fields aimed at facilitating neuroplasticity and functional recovery. Their lead program is currently being evaluated in the EMAGINE pivotal trial for ischemic stroke patients in the sub-acute phase. By providing a portable, cloud-connected device, BrainQ aims to transition neurorehabilitation from clinical settings to the home environment. The company has received FDA Breakthrough Device Designation for its innovative approach to treating neurological disabilities.